Triple Antithrombotic Therapy vs. Double Antithrombotic Therapy: One Scenario, 8 Questions, Many Conclusions

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Atrial fibrillation patients undergoing percutaneous coronary intervention often receive triple antithrombotic therapy (dual antiplatelet plus oral anticoagulant).
• This regimen aims to prevent ischemic events but is associated with a significant increase in bleeding complications.
• Recent guideline updates from North America and Europe address this therapeutic dilemma.

Purpose of the Study:

• To compare the key differences between North American and European consensus documents on dual antiplatelet therapy.
• To critically examine the foundational studies underpinning these guidelines.
• To identify gaps and propose directions for future clinical trials in antithrombotic therapy.

Main Methods:

• Review and comparative analysis of major clinical studies.
• Synthesis of recommendations from North American and European expert consensus documents.
• Identification of evidence-based discrepancies and areas for further investigation.

Main Results:

• Triple therapy effectively reduces cerebrovascular and coronary ischemic events.
• A significant increase in bleeding incidence is a major drawback of current triple therapy protocols.
• Discrepancies exist between major international guidelines regarding optimal antithrombotic strategies.

Conclusions:

• Current evidence supports triple therapy for specific patient populations despite bleeding risks.
• Further research is crucial to refine antithrombotic strategies and minimize bleeding without compromising efficacy.
• Future trials should focus on personalized antithrombotic approaches for patients with atrial fibrillation and coronary stents.